ESR1 and neoplasm: Tumor size, lymph node metastasis, ER and PR status, HER2-neu status, the percentages of patients receiving adjuvant hormone therapy, and the ratio of the four subgroups with ER, PR, and HER2-neu status analyzed by IHC were not significantly different among the three groups.